Skip to main content

Rucaparib: First Global Approval


Rucaparib (Rubraca™) is an oral, small molecule, poly (ADP-ribose) polymerase inhibitor being developed by Clovis Oncology, Inc. (Boulder, CO, USA) for the treatment of solid tumours. It has been approved in the USA as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. A marketing authorization application for rucaparib for the same indication has been submitted to the European Medicines Agency. Rucaparib is also under phase II or III investigation in ovarian, breast and prostate cancer. This article summarizes the milestones in the development of rucaparib leading to this first approval for ovarian cancer.

This is a preview of subscription content, access via your institution.


  1. 1.

    Clovis Oncology Inc. Prescribing information for RubracaTM (rucaparib) tablets, for oral use. 2016. Accessed 9 Jan 2017.

  2. 2.

    Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016;12(12):1439–56.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Plummer R, Lorigan P, Steven N, et al. A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol. 2013;71(5):1191–9.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Clovis Oncology Inc. Clovis Oncology, Inc. receives license for worldwide development and commercialization rights to Pfizer’s oral and IV PARP inhibitor PF-01367338 [media release]. 2011.

  6. 6.

    Clovis Oncology. SEC filings: 10K annual report for 2013. 2013. Accessed 21 Feb 2017.

  7. 7.

    Lonza. Lonza and Clovis Oncology sign strategic long-term manufacturing agreement to secure supply of rucaparib [media release]. 2016.

  8. 8.

    Murai J, Huang SY, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13(2):433–43.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Kern KA, Zhang S, Shalinsky DR, et al. Comparative PARP enzyme inhibition of PF-01367338, olaparib, and MK-4827 [abstract no. e13552]. J Clin Oncol. 2011;29(Suppl 15). doi:10.1200/jco.2011.29.15_suppl.e13552

  10. 10.

    Murray J, Thomas H, Berry P, et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. 2014;110(8):1977–84.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Plummer R, Jones C, Middleton M, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2008;14(23):7917–23.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Drew Y, Ledermann J, Hall G, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. 2016;114(12):723–30.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Ihnen M, Zu Eulenburg C, Kolarova T, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther. 2013;12(6):1002–15.

  14. 14.

    Chuang HC, Kapuriya N, Kulp SK, et al. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat. 2012;134(2):649–59.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Robillard L, Lin K, Lopez-Casas PP, et al. Preclinical efficacy of the PARP inhibitor rucaparib (CO-338/AG014699/PF-01367338) in pancreatic cancer models with homologous recombination deficiencies (HRD) [abstract no. 249]. Eur J Cancer. 2014;50(Suppl 6):83.

    Article  Google Scholar 

  16. 16.

    Drew Y, Mulligan EA, Vong W-T, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103(4):334–46.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Al Rubaish SS, Xiong Y, Marchion D, et al. Development of a rucaparib response signature that shows in vitro predictive value to the PARP inhibitors, ABT-888 and olaparib in ovarian cancer cells [abstract no. 54]. Gynecol Oncol. 2014;133(Suppl 1):22.

    Article  Google Scholar 

  18. 18.

    Audrey LC, Vanessa C, Marie K. The PARP inhibitor, Rucaparib enhance the sensitivity to Trabectedin in soft tissue sarcomas cell lines and in patient xenograft model [abstract no. 3002]. Cancer Res. 2016;76(Suppl 14). doi:10.1158/1538-7445.AM2016-3002

  19. 19.

    Falzacappa MV, Ronchini C, Faretta M, et al. The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias. Mol Cancer Ther. 2015;14(4):889–98.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Daniel RA, Rozanska AL, Mulligan EA, et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br J Cancer. 2010;103(10):1588–96.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Hoch U, Charych D. Combining the long-acting topoisomerase 1-inhibitor etirinotecan pegol with the PARP inhibitor rucaparib to provide anti-tumor synergy without increased toxicity [abstract no. 33]. Eur J Cancer. 2014;50(Suppl 6):16–7.

    Article  Google Scholar 

  22. 22.

    Kotsopoulos IC, Begbie JA, Mukhopadhyay A, et al. In vitro single agent rucaparib cytotoxicity and cisplatin chemo-potentiation in cervical cancer cell lines [abstract no. IGCS-0702]. Int J Gynecol Cancer. 2016;26(Suppl 3):374.

    Google Scholar 

  23. 23.

    Porcelli L, Quatrale AE, Mantuano P, et al. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol. 2013;7(3):308–22.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Hunter JE, Willmore E, Irving JA, et al. NF-kappaB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene. 2012;31(2):251–64.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Nile DL, Rae C, Hyndman IJ, et al. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer. 2016;16(1):621.

    Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Cullinane C, Waldeck K, Eu P, et al. The PARP inhibitor, rucaparib enhances the antitumor activity of 177Lu-DOTA-octreotate radionuclide therapy in preclinical models of neuroendocrine tumor [abstract no. 1800]. Cancer Res. 2015;75(Suppl 15). doi:10.1158/1538-7445.AM2015-1800

  27. 27.

    McCrudden CM, O’Rourke MG, Cherry KE, et al. Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself. PLoS One. 2015;10(2):e0118187.

    Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Ali M, Kamjoo M, Thomas HD, et al. The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. Mol Cancer Ther. 2011;10(12):2320–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Ali M, Telfer BA, McCrudden C, et al. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res. 2009;15(19):6106–12.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    McCormick A, Nakjang S, Donoghue P, et al. The role of homologous recombination recovery in cisplatin and rucaparib resistance in ovarian cancer [abstract no. ESGO-0857]. Int J Gynecol Cancer. 2015;25(Suppl 9):627.

    Google Scholar 

  31. 31.

    McCormick A, Donoghue P, Dixon M, et al. Ovarian cancers harbour defects in non-homologous end joining resulting in resistance to rucaparib. Clin Cancer Res. 2016. doi:10.1158/1078-0432.ccr-16-0564.

    PubMed  Google Scholar 

  32. 32.

    Durmus S, Sparidans RW, van Esch A, et al. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res. 2015;32(1):37–46.

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Parrish KE, Cen L, Murray J, et al. Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system. Mol Cancer Ther. 2015;14(12):2735–43.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Sun Y, Ding H, Liu X, et al. INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells. Tumour Biol. 2014;35(5):4469–77.

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Kristeleit RS, Shapira-Frommer R, Oaknin A, et al. Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): analysis of pooled data from study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2) [abstract no. 856O]. In: European Society for Medical Oncology 2016 Congress. 2016.

  36. 36.

    Shapira-Frommer R, Oza A, Domchek SM, et al. A phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation [abstract no. 2746 plus poster]. Eur J Cancer. 2015;51(Suppl 3):S545.

    Article  Google Scholar 

  37. 37.

    Coleman RL, Swisher EM, Oza AM, et al. Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: a phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC) [abstract no. 5540 plus poster]. J Clin Oncol. 2016;34(Suppl).

  38. 38.

    Kristeleit RS, Burris HA, LoRusso P, et al. Phase 1/2 study of oral rucaparib: final phase 1 results [abstract no. 2573]. J Clin Oncol. 2014;32(Suppl 5).

  39. 39.

    Miller K, Tong Y, Jones DR, et al. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: final efficacy results of Hoosier Oncology Group BRE09-146 [abstract no. 1082]. J Clin Oncol. 2015;33(Suppl 15).

  40. 40.

    Domchek SM, Hendifar AE, McWilliams RR, et al. RUCAPANC: an open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation [abstract no. 4110 plus poster]. J Clin Oncol. 2016;34(Suppl).

  41. 41.

    Foundation Medicine Inc. FoundationFocus™ CDxBRCA: draft summary of technical information. 2017. Accessed 20 Feb 2017.

  42. 42.

    Clovis Oncology. Clovis Oncology announces Q2 2016 operating results and corporate update [media release]. 8 Aug 2016.

  43. 43.

    Toms C, Chopra N, Houlton L, et al. Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO) [abstract no. 219TiP]. Ann Oncol. 2016;27(Suppl 6).

Download references


The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Y.Y. Syed is a salaried employee of Adis, Springer SBM.

Author information



Corresponding author

Correspondence to Yahiya Y. Syed.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Syed, Y.Y. Rucaparib: First Global Approval. Drugs 77, 585–592 (2017).

Download citation


  • Ovarian Cancer
  • Objective Response Rate
  • Advanced Ovarian Cancer
  • Royalty Payment
  • Homologous Recombination Deficiency